NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Following a successful pre-clinical study, WellGen (www.wellgen.com) today announced that its proprietary theaflavin-rich black tea concentrate, already known to be anti-inflammatory, favorably affected critical biomarkers of diabetes.
